Form 4 for INCY Incyte
Accepted 2025-07-02 00:00:00 ET · period of report 2025-06-30 · accession 0000879169-25-000068 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-07-02 | 2025-06-30 | INCY | Issa Mohamed Khairie | EVP, Head of US Oncology | A - Grant | $0.00 | +27.8K | 76.5K | +57% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-30 | A | A | 27,812 | $0.00 | 76,483 | D | — | — | (F1) Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years from the vesting commencement date of January 6, 2025. The RSUs may be settled only for shares of common stock on a one-for-one basis. (F2) Including the June 30, 2025 grant, this includes an aggregate of 76,483 shares of common stock issuable pursuant to previously reported RSUs that have not vested. |